UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2005
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Transition Period from ___ to ___
Commission file number 0-12957
ENZON
----------------------------------------------------
Exact name of registrant as specified in its charter
DELAWARE 22-2372868
-------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
685 Route 202/206, Bridgewater, New Jersey 08807
------------------------------------------ ----------
(Address of principal executive offices) (Zip Code)
(908) 541-8600
(Registrant's telephone number, including area code)
Not Applicable
- -------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
----------
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes _X_ No__
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes X No__
Shares of Common Stock outstanding as of May 4, 2005: 43,858,705.
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(UNAUDITED)
MARCH 31, 2005 JUNE 30, 2004
--------------- -------------
*
ASSETS
Current assets:
Cash and cash equivalents $ 41,158 $ 77,532
Short-term investments 102,986 27,119
Accounts receivable, net 20,831 25,977
Inventories 16,651 11,215
Deferred tax and other current assets 17,276 12,382
--------- ---------
Total current assets 198,902 154,225
--------- ---------
Other assets:
Property and equipment, net 33,518 34,859
Marketable securities 65,893 81,582
Investments in equity securities 15,848 37,906
Amortizable intangible assets, net 180,617 194,067
Goodwill 150,985 150,985
Deferred tax and other assets 70,262 68,786
--------- ---------
517,123 568,185
--------- ---------
Total assets $ 716,025 $ 722,410
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 10,821 $ 8,663
Accrued expenses 18,206 23,001
--------- ---------
Total current liabilities 29,027 31,664
--------- ---------
Other liabilities 899 1,655
Notes payable 400,000 400,000
--------- ---------
400,899 401,655
--------- ---------
Commitments and contingencies
Stockholders' equity:
Common stock-$.01 par value, authorized
90,000,000 shares; issued and
outstanding 43,858,705 shares at March 31, 2005
and 43,750,934 shares at June 30, 2004 439 438
Additional paid-in capital 323,354 322,486
Accumulated other comprehensive loss (3,010) (5,035)
Deferred compensation (3,804) (3,571)
Accumulated deficit (30,880) (25,227)
--------- ---------
Total stockholders' equity 286,099 289,091
--------- ---------
Total liabilities and stockholders' equity $ 716,025 $ 722,410
========= =========
* Condensed from audited financial statements.
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
2
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
THREE MONTHS ENDED NINE MONTHS ENDED
MARCH 31, MARCH 31,
------------------------- --------------------------
2005 2004 2005 2004
--------- --------- ---------- ------------
Revenues:
Product sales, net $ 21,224 $ 27,993 $ 75,712 $ 80,665
Manufacturing revenue 4,359 5,035 12,335 8,826
Royalties 12,705 11,103 32,899 36,461
Contract revenue 451 248 1,163 769
--------- --------- --------- ---------
Total revenues 38,739 44,379 122,109 126,721
--------- --------- --------- ---------
Costs and expenses:
Cost of product sales and manufacturing revenue 9,024 12,458 32,306 35,195
Research and development 12,942 10,772 31,874 24,711
Selling, general and administrative 13,658 12,500 39,630 35,187
Amortization of acquired intangible assets 3,339 3,358 10,091 10,074
Acquired in-process research and development -- 12,000 -- 12,000
--------- --------- --------- ---------
Total costs and expenses 38,963 51,088 113,901 117,167
--------- --------- --------- ---------
Operating (loss) income (224) (6,709) 8,208 9,554
--------- --------- --------- ---------
Other income (expense):
Investment income, net 1,116 11,564 2,859 12,744
Interest expense (4,957) (4,957) (14,871) (14,871)
Other, net (3,230) (337) (5,173) 71
--------- --------- --------- ---------
(7,071) 6,270 (17,185) (2,056)
--------- --------- --------- ---------
(Loss) income before tax benefit (7,295) (439) (8,977) 7,498
Income tax benefit (2,718) (5,505) (3,324) (2,691)
--------- --------- --------- ---------
Net (loss) income (4,577) $ 5,066 (5,653) $ 10,189
========= ========= ========= =========
Basic (loss) earnings per common share $ (0.11) $ 0.12 $ (0.13) $ 0.24
========= ========= ========= =========
Diluted (loss) earnings per common share $ (0.11) $ 0.12 $ (0.13) $ 0.23
========= ========= ========= =========
Weighted average number of common shares outstanding - basic 43,490 43,368 43,481 43,322
========= ========= ========= =========
Weighted average number of common shares and dilutive
potential common shares outstanding 43,490 43,817 43,481 43,657
========= ========= ========= =========
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
3
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
NINE MONTHS ENDED
MARCH 31,
-------------------------
2005 2004
---------- ----------
Cash flows from operating activities:
Net (loss) income ($ 5,653) $ 10,189
Adjustments to reconcile net (loss) income to net cash
provided by operating activities:
Depreciation and amortization 17,007 16,487
Non-cash expense for restricted stock grants 429 1,132
Loss (gain) on sale of investments 3,541 (10,997)
Non-cash loss (gain) related to equity collar
arrangement 1,781 (82)
Amortization of debt issue costs 1,371 1,371
Amortization of bond premium/discount 2,049 409
Deferred income taxes (3,043) (4,618)
Changes in operating assets and liabilities (4,663) (5,433)
--------- ---------
Net cash provided by operating activities 12,819 8,458
--------- ---------
Cash flows from investing activities:
Purchase of property and equipment (2,210) (4,640)
Proceeds from sale of equity investment 15,335 17,375
Proceeds from sale of marketable securities 74,000 49,744
Purchase of marketable securities (136,525) (44,450)
--------- ---------
Net cash (used in) provided by investing (49,400) 18,029
activities
--------- ---------
Cash flows from financing activities:
Proceeds from exercise of common stock options 207 431
--------- ---------
Net cash provided by financing activities 207 431
--------- ---------
Net (decrease) increase in cash and cash equivalents (36,374) 26,918
Cash and cash equivalents at beginning of period 77,532 44,452
--------- ---------
Cash and cash equivalents at end of period $ 41,158 $ 71,370
========= =========
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
4
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(1) ORGANIZATION AND BASIS OF PRESENTATION
The unaudited condensed consolidated financial statements have been
prepared from the books and records of Enzon Pharmaceuticals, Inc. and its
subsidiaries ("Enzon" or the "Company") in accordance with United States
generally accepted accounting principles ("GAAP") for interim financial
information and Rule 10-01 of Regulation S-X. Accordingly, they do not include
all of the information and footnotes required for complete annual financial
statements. The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. In the opinion of management,
all adjustments (consisting only of normal and recurring adjustments) considered
necessary for a fair presentation have been included. Certain prior year
balances have been reclassified to conform to the current period presentation.
Interim results are not necessarily indicative of the results that may be
expected for the year. The interim consolidated financial statements should be
read in conjunction with the consolidated financial statements and the notes
thereto included in the Company's latest annual report on Form 10-K/A.
(2) MARKETABLE SECURITIES
The Company classifies its investments in debt and marketable equity
securities, including auction rate securities, as available-for-sale. The
Company classified those investments available for current operations with
maturities of one year or less as current assets. Debt and marketable equity
securities are carried at fair value, with the unrealized gains and losses
(which are deemed to be temporary), net of related tax effect, included in the
determination of comprehensive income and reported in stockholders' equity. The
fair value of substantially all securities is determined by quoted market
prices.
At March 31, 2005 and June 30, 2004 the Company held auction rate
securities for which interest or dividend rates are generally re-set for periods
of up to 90 days. The auction rate securities outstanding at March 31, 2005 and
June 30, 2004 were investments in state government bonds and corporate
securities. In the third quarter of 2005, the Company reclassified its auction
rate securities from cash and cash equivalents to either short-term investments
or marketable securities, depending upon the instrument's maturity date. At
March 31, 2005, the Company held auction rate securities with contractual
maturities between 2005 and 2009.
The cost of the debt securities is adjusted for amortization of
premiums and accretion of discounts to maturity. The amortization, along with
realized gains and losses, is included in interest income. The cost of
securities is based on the specific identification method.
A decline in the market value of any security below cost that is deemed
to be other-than-temporary results in a reduction in carrying amount to fair
value. The impairment is charged to earnings and a new cost basis for the
security is established. Dividend and interest income are recognized when
earned.
The amortized cost, gross unrealized holding gains or losses, and fair
value for the Company's available-for-sale securities by major security type as
of March 31, 2005 were as follows (in thousands):
Gross Gross
Amortized Unrealized Unrealized
Cost Holding Gains Holding Losses Fair Value*
--------------- ---------------- ---------------- ----------------
U.S. Government Agency Debt $ 91,357 - $ (689) $ 90,668
U.S. Corporate Debt 70,942 12 (768) 70,186
Auction Rate Securities 8,025 - - 8,025
--------------- ---------------- ---------------- ----------------
$170,324 $12 $(1,457) $168,879
=============== ================ ================ ================
* $102,986 is included in short-term investments and $65,893 is included in
marketable securities.
5
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The amortized cost, gross unrealized holding gains or losses, and fair
value for the Company's available-for-sale securities by major security type at
June 30, 2004 were as follows (in thousands):
Gross Gross
Amortized Unrealized Unrealized
Cost Holding Gains Holding Losses Fair Value*
---------------- ---------------- ---------------- ----------------
U.S. Government Agency Debt $ 24,017 $ 5 ($ 351) $ 23,671
U.S. Corporate Debt 71,832 6 (808) 71,030
Auction Rate Securities 14,000 - - 14,000
---------------- ---------------- ---------------- ----------------
$109,849 $11 ($1,159) $108,701
================ ================ ================ ================
* $27,119 is included in short-term investments and $81,582 is included in
marketable securities.
6
(3) COMPREHENSIVE INCOME
Statement of Financial Accounting Standards ("SFAS") No. 130,
"Reporting Comprehensive Income", requires unrealized gains and losses on the
Company's available-for-sale securities to be included in other comprehensive
income.
The following table reconciles net (loss) income to comprehensive
(loss) income (in thousands):
THREE MONTHS ENDED NINE MONTHS ENDED
MARCH 31, MARCH 31,
------------------------ ----------------------
2005 2004 2005 2004
---------- ---------- --------- ---------
Net (loss) income ($4,577) $5,066 ($5,653) $10,189
---------- ---------- --------- ---------
Other comprehensive income:
Unrealized (loss) gain on securities
that arose during the period (488) 324 (297) 3
Unrealized (loss) gain on NPS
investment arising during the
period - - (1,014) 1,824
Foreign currency translation 3 - 16 -
Reclassification adjustment
for loss (gain) included in net (loss)
income 2,020 227 3,320 (222)
---------- ---------- --------- ---------
Total other comprehensive income 1,535 551 2,025 1,605
---------- ---------- --------- ---------
Comprehensive (loss) income ($3,042) $5,617 ($3,628) $11,794
========== ========== ========= =========
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(4) EARNINGS PER COMMON SHARE
Basic earnings per share is computed by dividing the net (loss) income
by the weighted average number of shares of Common Stock issued and outstanding
during the periods. For purposes of calculating diluted earnings per share for
the three and nine months ended March 31, 2005 and 2004, the denominator
includes both the weighted average number of shares of Common Stock outstanding
and the number of potentially dilutive Common Stock equivalents if the inclusion
of such Common Stock equivalents was not anti-dilutive. As of March 31, 2005 and
2004, the Company had 10.1 million and 10.8 million, respectively, of
potentially dilutive Common Stock equivalents that are excluded from the
dilutive earnings per share calculations, as the effect of the inclusion would
be anti-dilutive.
The following table reconciles the basic and diluted earnings per share
calculations (in thousands):
THREE MONTHS ENDED NINE MONTHS ENDED
MARCH 31, MARCH 31,
---------------------- ----------------------
2005 2004 2005 2004
--------- --------- -------- ----------
Net (loss) income ($4,577) $5,066 ($5,653) $10,189
========= ========= ======== ==========
Weighted average number of common 43,490 43,368 43,481 43,322
shares issued and outstanding - basic
Effect of dilutive common stock equivalents:
Stock options -- 449 -- 335
--------- --------- -------- ----------
43,490 43,817 43,481 43,657
========= ========= ======== ==========
(5) STOCK-BASED COMPENSATION
As permitted by SFAS No. 123, "Accounting for Stock-Based
Compensation", the Company accounts for stock-based compensation arrangements in
accordance with the provisions of Accounting Principals Board ("APB") Opinion
No. 25, "Accounting for Stock Issued to Employees" and related interpretations.
Compensation expense for stock options issued to employees is based on the
difference between the fair value of the Company's stock and the exercise price
of the option on the date of grant. Stock-based compensation reflected in net
(loss) income is attributed to restricted stock. No stock-based employee
compensation cost is reflected in net (loss) income with respect to stock
options granted to employees as options are granted at exercise prices equal to
the market value of the underlying Common Stock at the date of grant.
7
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table illustrates the effect on net (loss) income and net
(loss) earnings per share if the Company had applied the fair value recognition
provisions of SFAS No. 123 to stock-based compensation (in thousands, except per
share data):
THREE MONTHS ENDED NINE MONTHS ENDED
MARCH 31, MARCH 31,
------------------------ --------------------------
2005 2004 2005 2004
---------- ---------- ---------- -------------
Net (loss) income:
As reported ($4,577) $5,066 ($5,653) $10,189
Add stock-based employee
compensation expense included in
reported net (loss) income, net of tax (1) 35 277 270 718
Deduct total stock-based employee
compensation expense determined
under fair-value-based method for all
awards, net of tax (1) (2,303) (3,040) (9,073) (8,588)
---------- ---------- ---------- -------------
Pro forma net (loss) income ($6,845) $2,303 ($14,456) $2,319
========== ========== ========== =============
Earnings per common share - basic:
As reported ($0.11) $0.12 ($0.13) $0.24
Pro forma ($0.16) $0.05 ($0.33) $0.05
Earnings per common share - diluted:
As reported ($0.11) $0.12 ($0.13) $0.23
Pro forma ($0.16) $0.05 ($0.33) $0.05
(1) Information for 2005 and 2004 has been adjusted for income taxes using
estimated tax rates of 37% and 29%, respectively.
(6) INVENTORIES
As of March 31, 2005 and June 30, 2004 inventories consisted of the
following (in thousands):
MARCH 31, 2005 JUNE 30, 2004
------------------ ----------------
Raw materials $ 4,802 $ 3,143
Work in process 2,928 3,716
Finished goods 8,921 4,356
------------------ ----------------
$16,651 $11,215
================== ================
8
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(7) INTANGIBLE ASSETS
As of March 31, 2005 and June 30, 2004 intangible assets consisted of
the following (in thousands):
MARCH 31, JUNE 30, ESTIMATED
2005 2004 USEFUL LIVES
------------- ------------ --------------
Product Patented Technology $ 64,400 $ 64,400 12 years
Manufacturing Patent 18,300 18,300 12 years
NDA Approval 31,100 31,100 12 years
Trade name and Other Product Rights 80,000 80,000 15 years
Manufacturing Contract 2,200 2,200 3 years
Patent 1,906 2,092 15 years
Product Acquisition Costs 26,194 26,194 10-14 years
------------- ------------
224,100 224,286
Less: Accumulated Amortization 43,483 30,219
------------- ------------
$180,617 $194,067
============= ============
Amortization charged to operations relating to intangible assets
totaled $4.5 million of which $1.1 million is classified in cost of product
sales and manufacturing revenue for each of the three months ended March 31,
2005 and 2004. For each of the nine month periods ended March 31, 2005 and 2004
amortization charged to operations relating to intangible assets totaled $13.4
million, of which $3.4 million is classified in cost of product sales and
manufacturing revenue. Amortization expense for these intangibles for the next
five fiscal years is expected to be approximately $17.9 million per year.
(8) GOODWILL
On November 22, 2002, the Company acquired the North American rights and
operational assets associated with the development, manufacture, sales and
marketing of ABELCET(R) (amphotericin B lipid complex injection) (the "North
American ABELCET business") from Elan Corporation, plc ("Elan") for $360.0
million plus acquisition costs of approximately $9.3 million. The acquisition is
being accounted for by the purchase method of accounting in accordance with SFAS
No. 141 "Business Combinations". The amount assigned to goodwill in connection
with the acquisition of the North American ABELCET business was recorded at
$151.0 million. In accordance with SFAS No. 142, "Goodwill and Other Intangible
Assets," the Company does not amortize goodwill but rather reviews it at least
annually for impairment. For income tax purposes, the entire amount of goodwill
is deductible and is being amortized over a 15 year period.
(9) CASH FLOW INFORMATION
The Company considers all highly liquid securities with original
maturities of three months or less to be cash equivalents. For each of the nine
month periods ended March 31, 2005 and 2004, cash payments for interest were
$18.0 million. Income tax payments for the nine months ended March 31, 2005 and
2004, were $590,000 and $3.6 million, respectively.
(10) INCOME TAXES
The Company recognized a tax benefit for the nine months ended March
31, 2005 at an estimated annual effective tax rate of 37%, which is based on the
projected income tax benefit and taxable loss for the fiscal year ending June
30, 2005. During the three and nine months ended March 31, 2005 the Company
recorded a valuation allowance of $701,000 and $1.4 million, respectively,
related to capital loss carryforwards generated during the periods related to
the sale of a portion of its equity investment in NPS Pharmaceuticals, Inc.
("NPS") and certain investments in debt and equity securities.
9
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
At March 31, 2005, the Company has approximately $71.2 million in net
deferred tax assets because management concluded that it is more likely than not
that the net deferred tax assets will be realized, including the net operating
losses from operating activities and stock option exercises, based on future
operations. As of March 31, 2005, the Company carries a valuation allowance of
$17.9 million with respect to certain capital loss carryforwards, deductible
temporary differences that would result in a capital loss carryforward when
realized and federal research and development tax credits, as the ultimate
utilization of such losses and credits is not deemed likely. Events, such as a
sustained decline in the Company's product revenues and/or increased expenses,
could result in a revision to the Company's projected future taxable income, and
accordingly, the need for a valuation allowance based upon the ultimate
realizability of its net operating loss carryforwards, research and development
tax credits and other deferred tax assets. The Company's federal and state
operating loss carryforwards will begin to expire in 2009 and 2006,
respectively, and the federal and state research and development credits will
begin to expire in 2006 and 2021, respectively. The Company will continue to
assess the need for such valuation allowance based on analyses of operating
results and projections of future operating performance of the Company.
During the three months ended March 31, 2004, the Company recorded a
net tax benefit of approximately $5.5 million related primarily to the reversal
of a $3.8 million deferred tax asset valuation allowance for the write-down in a
prior year of Enzon's equity investment in Nektar Therapeutics, which was sold
during the quarter ended March 31, 2004. The sale resulted in a gain of
approximately $11.0 million. The benefit was also due to the reduction of
Enzon's estimated taxable income and effective tax rate to 29% as compared to
35% used in previous quarters and a payment during the three months ended March
31, 2004 of $12.0 million to INEX Pharmaceuticals related to acquired in-process
research and development. The tax provision recognized for the nine months ended
March 31, 2004 is based on the estimated annual effective tax rate of 29%. In
addition, the tax effect of the gain on the sale of Nektar Convertible Preferred
Stock and the acquired in process research and development charge was recognized
during the three months ended March 31, 2004, the period in which the items
occurred.
During the three and nine month period ended March 31, 2004, the
Company received $254,000 for the sale of certain New Jersey state net operating
loss carryforwards and also purchased certain New Jersey state net operating
loss carryforwards for $1.5 million, which were recorded as deferred tax assets.
(11) BUSINESS SEGMENTS
A single management team that reports to the Chief Executive Officer
comprehensively manages the Company's operations. The Company does not operate
separate lines of business or separate business entities with respect to any of
its approved products or product candidates or contract manufacturing. In
addition, the Company does not conduct any operations outside of the United
States and Canada. The Company does not prepare discrete financial statements
with respect to separate product or contract manufacturing areas. Accordingly,
the Company does not have separately reportable segments as defined by SFAS No.
131, "Disclosures about Segments of an Enterprise and Related Information".
(12) DERIVATIVE INSTRUMENTS
In August 2003, the Company entered into a Zero Cost Protective Collar
arrangement with a financial institution to reduce the exposure associated with
1.5 million shares of NPS common stock, which the Company received as part of a
merger termination agreement with NPS. The termination agreement imposed a limit
on the maximum number of shares that can be transferred each month. The terms of
the collar arrangement are structured so that the Company's investment in NPS
stock, when combined with the value of the collar, should secure ultimate cash
proceeds in the range of 85%-108% of the negotiated fair value per share of
$23.47 (representing a 4.85% discount off of the closing price of NPS common
stock on the day before the collar was executed). The collar is considered a
derivative fair value hedging instrument (the "Derivative") under SFAS No. 133,
"Accounting For Derivative Instruments and Hedging Activities" and as such, the
Company periodically measures its fair value and recognizes the Derivative as an
asset or a liability. Changes in the fair value of NPS stock are recorded in
other comprehensive income (See Note 3) when the value of the NPS stock is
within the range of the collar. Changes in the fair value of NPS stock outside
the range of the collar and changes in the fair value of the Derivative are
charged or credited to the consolidated statement of operations when the
Derivative is designated and effective as a fair value hedge.
As of March 31, 2005, the market value of NPS common stock was $12.63
per share, which is below the bottom of the collar. When the underlying shares
become unrestricted and freely tradable the Company is required to deliver a
corresponding number of underlying shares to the financial institution as posted
collateral. In order to deliver such shares, during the nine months ended March
31, 2005, the Company sold and re-purchased 375,000 shares of NPS common stock.
The unrealized gain previously included in other comprehensive income prior to
the sale and re-purchase with respect to these shares aggregating $38,000 for
the nine months ended March 31, 2005, was recognized in the Condensed
Consolidated Statements of Operations and is included in other income (expense).
There were no sales and repurchases of stock for the three months ended March
31, 2005. During the three and nine month periods ended March 31, 2004, the
Company sold and re-purchased 315,000 shares and 690,100 shares of NPS common
stock, respectively. The unrealized gain previously recognized under other
comprehensive income with respect to these shares aggregating $504,000 and $1.1
million was recognized in the Condensed Consolidated Statements of Operations
for the three and nine months ended March 31, 2004, respectively.
10
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
During February 2005, the second portion of the Derivative matured
resulting in net proceeds of $7.5 million, which represented the floor of the
collar or $19.95 per share. The closing price of NPS common stock was $14.46 on
the day the second portion of the collar matured. The unrealized loss of
approximately $2.0 million and $3.4 million previously included in other
comprehensive income (loss) was recognized in the Consolidated Statement of
Operations and included in other income (expense) for the three and nine months
ended March 31, 2005, respectively.
The changes during the periods in the time value component of the
collar are a loss of $1.2 million and a loss of $1.8 million for the three and
nine months ended March 31, 2005 and a loss of $318,000 and gain of $83,000 for
the three and nine months ended March 31, 2004, respectively. These changes are
recorded in other income (expense) in the Condensed Consolidated Statement of
Operations. The remainder of the collar will mature on two separate maturity
dates in May 2005 and August 2005, at which time the Company will receive the
proceeds from the sale of the securities. The amount due at each maturity date
will be determined based on the market value of NPS common stock on such
maturity date. The contract requires the Company to maintain a minimum cash
balance of $30.0 million and additional collateral of up to $10.0 million, as
defined under certain circumstances with the financial institution. The
Derivative is subject to certain adjustments in the event the Company receives a
dividend from NPS.
(13) NEW ACCOUNTING PRONOUNCEMENTS
In response to the enactment of the American Job Creation Act of 2004
(the "Jobs Act") on October 22, 2004 the Financial Accounting Standards Board
(FASB) issued FASB Staff Position (FSP) 109-1, Application of FASB Statement No.
109, Accounting for Income Taxes, for the Tax Deduction Provided to U.S. Based
Manufacturers by the American Job Creation Act of 2004.
FSP No. 109-1 clarifies how to apply SFAS No. 109 to the new law's tax
deduction for income attributable to "domestic production activities." The fully
phased-in deduction is up to nine percent of the lesser of taxable income or
"qualified production activities income." The staff position requires that the
deduction be accounted for as a special deduction in the period earned, not as a
tax-rate reduction. As a result, the Company will recognize a reduction in its
provision for income taxes for domestic production activities in the quarterly
periods in which the Company is eligible for the deduction.
In November 2004, the FASB issued SFAS No. 151, "Inventory Costs--An
Amendment of ARB No. 43, Chapter 4" ("SFAS 151"). SFAS 151 amends the guidance
in ARB No. 43, Chapter 4, "Inventory Pricing," to clarify the accounting for
abnormal amounts of idle facility expense, freight, handling costs, and wasted
material (spoilage). Among other provisions, the new rule requires that items
such as idle facility expense, excessive spoilage, double freight, and
rehandling costs be recognized as current-period charges regardless of whether
they meet the criterion of "so abnormal" as stated in ARB No. 43. Additionally,
SFAS 151 requires that the allocation of fixed production overheads to the costs
of conversion be based on the normal capacity of the production facilities. SFAS
151 is effective for fiscal years beginning after June 15, 2005 and is required
to be adopted by the Company in the first quarter of fiscal 2006, beginning on
July 1, 2005. The Company is currently evaluating the effect that the adoption
of SFAS 151 will have on its consolidated results of operations and financial
condition and does not expect SFAS 151 to have a material impact.
11
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In December 2004, the FASB issued SFAS No. 123 (revised 2004),
"Share-Based Payment" ("SFAS 123R"), which replaces SFAS No. 123, "Accounting
for Stock-Based Compensation," ("SFAS 123") and supercedes APB Opinion No. 25,
"Accounting for Stock Issued to Employees." SFAS 123R requires all share-based
payments to employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair values beginning with
the first annual reporting period that begins after June 15, 2005, with early
adoption encouraged. The pro forma disclosures previously permitted under SFAS
123 no longer will be an alternative to financial statement recognition. The
Company is required to adopt SFAS 123R no later than July 1, 2005. Under SFAS
123R, Enzon must determine the appropriate fair value model to be used for
valuing share-based payments, the amortization method for compensation cost and
the transition method to be used at date of adoption. The transition methods
include prospective and retroactive adoption options. Under the retroactive
option, prior periods may be restated either as of the beginning of the year of
adoption or for all periods presented. The prospective method requires that
compensation expense be recorded for all unvested stock options and restricted
stock at the beginning of the first quarter of adoption of SFAS 123R, while the
retroactive methods would record compensation expense for all unvested stock
options and restricted stock beginning with the first period restated. The
Company is evaluating the requirements of SFAS 123R and expects that the
adoption of SFAS 123R will have a material impact on its consolidated results of
operations and earnings per share. The Company has not yet determined the method
of adoption or the effect of adopting SFAS 123R, and has not determined whether
the adoption will result in amounts that are similar to the current pro forma
disclosures under SFAS 123.
In December 2004, the FASB issued SFAS No. 153, "Exchanges of Nonmonetary
Assets--An Amendment of APB Opinion No. 29, Accounting for Nonmonetary
Transactions" ("SFAS 153"). SFAS 153 eliminates the exception from fair value
measurement for nonmonetary exchanges of similar productive assets in paragraph
21(b) of APB Opinion No. 29, "Accounting for Nonmonetary Transactions," and
replaces it with an exception for exchanges that do not have commercial
substance. SFAS 153 specifies that a nonmonetary exchange has commercial
substance if the future cash flows of the entity are expected to change
significantly as a result of the exchange. SFAS 153 is effective for the fiscal
periods beginning after June 15, 2005 and is required to be adopted by us
beginning on July 1, 2005. The Company is currently evaluating the effect that
the adoption of SFAS 153 will have on its consolidated results of operations and
financial condition but does not expect it to have a material impact.
In March 2004, the Financial Accounting Standards Board's (FASB)
Emerging Issues Task Force (EITF) released Issue 03-01, "Meaning of Other Than
Temporary Impairment", which addressed other-than-temporary impairment for
certain debt and equity investments. Various disclosure requirements of Issue
03-01 had been finalized previous to issuance and were required as of June 30,
2004. The recognition and measurement requirements of Issue 03-01, and other
disclosure requirements not already implemented, were effective for periods
beginning after June 15, 2004. In September 2004, the FASB staff issued FASB
Staff Position (FSP) EITF 03-1-1, which delayed the effective date for certain
measurement and recognition guidance contained in Issue 03-1. The FSP requires
the application of pre-existing "other-than-temporary" guidance during the
period of delay until a final consensus is reached. The disclosure requirements
set forth in Issue 03-01 were not delayed as a result of the issued FSP. The
Company's management does not anticipate the issuance of the final consensus
will have a material impact on financial condition, the results of operations,
or liquidity.
(14) INEX AGREEMENT
In March 2005, the Company terminated the agreements entered into with
Inex Pharmaceuticals, Inc. in January 2004 regarding the development and
commercialization of Inex's proprietary oncology product MARQIBO(R) (vincristine
sulfate liposomes injection). Under the terminated MARQIBO Agreements, the
Company shared the costs of clinical development with Inex and received the
exclusive commercialization rights for MARQIBO for all indications in the United
States, Canada and Mexico. In January 2005, the United States Food and Drug
Administration (the "FDA") provided an action letter detailing MARQIBO as "not
approvable" under the FDA's accelerated approval regulations for relapsed
aggressive non-Hodgkin's lymphoma. The FDA's response also recommended that
additional randomized controlled studies would need to be conducted prior to
re-applying for approval. After a strategic analysis of the FDA's
recommendation, required investment, development timeframe, and associated
development risks, the Company concluded it would be in Enzon's best interest to
redirect this investment to pursue other opportunities. In connection with the
termination, Enzon paid Inex a final payment of $5.0 million in satisfaction of
all of the Company's financial obligations under the MARQIBO Agreements,
including development expenses and milestone payments. The payment was charged
to research and development in the Company's Condensed Consolidated Statement of
Operations.
(15) SUBSEQUENT EVENTS
Effective April 21, 2005, the Company's executive vice president, finance
and chief financial officer (the "CFO") resigned, for personal reasons. In
connection with the CFO's resignation, the Company entered into a Separation
Agreement effective as of April 21, 2005.
12
ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Pursuant to the Separation Agreement, the CFO will receive a cash
payment equal to his annual base salary, the pro rata amount of his annual
target bonus (which is 50% of his base salary) for fiscal year 2005, and his
annual target bonus for fiscal year 2006. In addition, the period of time he has
to exercise certain of his options is extended to 18 months; the vesting of some
of his options and restricted stock was accelerated; and he will be reimbursed
for his medical insurance premiums for up to 36 months. The Company will record
a severance charge in the quarter ended June 30, 2005.
Based upon increasingly competitive conditions in the intravenous
antifungal market and the recent discontinuance of certain development projects
in the Company's research and development pipeline, Enzon is realigning its cost
structure through a restructuring. The Company expects to incur charges of $1.5
million to $2.5 million during the quarter ending June 30, 2005. These costs,
all of which involve future cash expenditures, are comprised primarily of
employee termination benefits.
13
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
LIQUIDITY AND CAPITAL RESOURCES
Total cash reserves, which include cash, cash equivalents, short-term
investments and marketable securities, were $210.0 million as of March 31, 2005,
as compared to $186.2 million as of June 30, 2004. The increase is primarily due
to net cash provided by operating activities and proceeds from the liquidation
of a portion of the shares of NPS Pharmaceuticals, Inc. common stock that we
own. We invest our excess cash primarily in United States government-backed
securities and investment-grade corporate debt securities and auction rate
securities.
During the nine months ended March 31, 2005, net cash provided by
operating activities was $12.8 million, compared to $8.5 million for the nine
months ended March 31, 2004. Net cash provided by operations was principally due
to non-cash charges included in our net loss of $5.7 million for the nine months
ended March 31, 2005. Non-cash charges totaled $26.2 million and were primarily
attributable to depreciation and amortization of $17.0 million, losses on sales
of investments of $3.5 million, amortization of bond premium/discount of $2.0, a
loss on our equity collar arrangement related to our investment in NPS common
stock of $1.8 million, and amortization of debt issue costs of $1.4 million.
Non-cash charges were partially offset by $7.7 million in changes in deferred
income taxes and operating assets and liabilities.
Cash used in investing activities totaled $49.4 million for the nine
months ended March 31, 2005 compared to cash provided by investing activities of
$18.0 million for the nine months ended March 31, 2004. Cash used in investing
activities during the nine months ended March 31, 2005, consisted of $2.2 of
capital expenditures and investments in marketable securities of $136.5 million,
offset by $74.0 million in proceeds from the sale of marketable securities and
$15.3 million in proceeds from the liquidation of a portion of our investment in
NPS common stock.
As of March 31, 2005, we had $400.0 million of convertible subordinated
notes outstanding. The notes bear interest at an annual rate of 4.5%. Interest
is payable on January 1 and July 1 of each year. Accrued interest on the notes
was $4.5 million as of March 31, 2005. The holders may convert all or a portion
of the notes into common stock at any time on or before July 1, 2008. The notes
are convertible into our common stock at a conversion price of $70.98 per share,
subject to adjustment in certain events. The notes are subordinated to all
existing and future senior indebtedness. We may redeem any or all of the notes
at specified redemption prices, plus accrued and unpaid interest to the day
preceding the redemption date. As of March 31, 2005 the redemption price of the
notes is 102.571% of the principal amount. The notes will mature on July 1, 2008
unless converted earlier, redeemed at our option or redeemed at the option of
the note holder upon a fundamental change, as described in the indenture for the
notes. Neither we nor any of our subsidiaries are subject to any financial
covenants under the indenture. In addition, neither we nor any of our
subsidiaries are restricted under the indenture from paying dividends, incurring
debt, or issuing or repurchasing our securities.
In August 2003, the Company entered into a Zero Cost Protective Collar
arrangement with a financial institution to reduce the exposure associated with
1.5 million shares of NPS common stock, which the Company received as part of a
merger termination agreement with NPS. During the nine months ended March 31,
2005 we received proceeds of $15.0 million related to the maturation of two
portions of the derivative. The remainder of the collar will mature on two
separate maturity dates in May 2005 and August 2005, at which time the Company
will receive the proceeds from the sale of the securities which we estimate
after taking into account the effect of the collar will be in the range of $15.0
million to $19.0 million. The amount due at each maturity date will be
determined based on the market value of NPS common stock on such maturity date.
The contract requires the Company to maintain a minimum cash balance of $30.0
million and additional collateral of up to $10.0 million, as defined under
certain circumstances with the financial institution. The derivative is subject
to certain adjustments in the event the Company receives a dividend from NPS.
Our current sources of liquidity are our cash and cash equivalents,
interest earned on such cash and cash equivalents, short-term investments,
marketable securities, sales of ADAGEN(R), ONCASPAR(R), DEPOCYT(R) and
ABELCET(R), royalties earned, which are primarily related to sales of
PEG-INTRON(R), and contract manufacturing revenue. In addition, we intend to
sell our remaining position in NPS as discussed above. Based upon our currently
planned research and development activities and related costs and our current
sources of liquidity, we anticipate our current cash reserves and expected cash
flow from operations will be sufficient to meet our capital, debt service and
operational requirements for the foreseeable future.
14
While we believe that our cash, cash equivalents and investments will
be adequate to satisfy our capital needs for the foreseeable future, we may seek
additional financing, such as through future offerings of equity or debt
securities or agreements with collaborators with respect to the development and
commercialization of products, to fund future operations and potential
acquisitions. We cannot assure you, however, that we will be able to obtain
additional funds on acceptable terms, if at all.
OFF-BALANCE SHEET ARRANGEMENTS
As part of our ongoing business, we do not participate in transactions
that generate relationships with unconsolidated entities or financial
partnerships, such as entities often referred to as structured finance or
special purpose entities ("SPE"), which would have been established for the
purpose of facilitating off-balance sheet arrangements or other contractually
narrow limited purposes. As of March 31, 2005, we were not involved in any SPE
transactions.
CONTRACTUAL OBLIGATIONS
Our major outstanding contractual obligations relate to our operating
leases, inventory purchase commitments, convertible debt, and license agreements
with collaborative partners.
In March 2005, we terminated the agreements we entered into with Inex
Pharmaceuticals, Inc. in January 2004 regarding the development and
commercialization of Inex's proprietary oncology product MARQIBO(R) (vincristine
sulfate liposomes injection). Under the terminated MARQIBO Agreements, we shared
the costs of clinical development with Inex and received the exclusive
commercialization rights for MARQIBO for all indications in the United States,
Canada and Mexico. In January 2005, the United States Food and Drug
Administration (the "FDA") provided an action letter detailing MARQIBO as "not
approvable" under the FDA's accelerated approval regulations for relapsed
aggressive non-Hodgkin's lymphoma. The FDA's response also recommended that
additional randomized controlled studies would need to be conducted prior to
re-applying for approval. After a strategic analysis of the FDA's
recommendation, required investment, development timeframe, and associated
development risks, we concluded it would be in the Company's best interest to
redirect this investment to pursue other opportunities. In connection with the
termination, we paid Inex a final payment of $5.0 million in satisfaction of all
of our financial obligations under the MARQIBO Agreements, including development
expenses and milestone payments. The payment was charged to research and
development in our Condensed Consolidated Statement of Operations.
Since June 30, 2004, there have been no other material changes with
respect to our contractual obligations as disclosed under Management's
Discussion and Analysis of Financial Condition and Results of Operations -
Contractual Obligations in our annual report on Form 10-K/A for the year ended
June 30, 2004.
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2005 AND 2004
REVENUES. Total revenues for the three months ended March 31, 2005 were
$38.7 million, as compared to $44.4 million for the three months ended March 31,
2004. The components of revenues are product sales, manufacturing revenue,
royalties we earn on the sale of our products by others and contract revenue.
Net product sales decreased by 24% to $21.2 million for the three
months ended March 31, 2005, as compared to $28.0 million for the three months
ended March 31, 2004. The decrease in sales was due to decreased sales of
ABELCET. Sales of ABELCET in North America decreased by $8.5 million to $9.1
million for the three months ended March 31, 2005, as compared to $17.6 million
for the three months ended March 31, 2004 due to increased competition in the
intravenous antifungal market. Sales of DEPOCYT increased by $483,000 to $1.8
million for the three months ended March 31, 2005 as compared to $1.4 million
for the three months ended March 31, 2004. DEPOCYT's growth over the prior year
was primarily attributable to increased sales and marketing efforts, as well as
a higher weighted average price. Sales of ONCASPAR increased by $652,000 to $5.5
million for the three months ended March 31, 2005 from $4.9 million for the
three months ended March 31, 2004. The increase in sales of ONCASPAR over the
prior year was primarily driven by a higher weighted average price. Sales of
ADAGEN increased by $644,000 for the three months ended March 31, 2005 to $4.8
million as compared to $4.1 million for the three months ended March 31, 2004
due to the timing of shipments. Historically, quarterly sales of ADAGEN
experience volatility because of the small number of patients on therapy.
15
Manufacturing revenue for the three months ended March 31, 2005
decreased by $676,000 to $4.4 million, as compared to $5.0 million for the
comparable period of the prior year, due to reduced orders from our contract
manufacturing customers. Manufacturing revenue is related to the manufacture and
sale of ABELCET for the international market and other manufacturing revenue.
Royalties for the three months ended March 31, 2005, increased by $1.6
million to $12.7 million as compared to $11.1 million for the three months ended
March 31, 2004. Royalties are principally comprised of royalties from sales of
PEG-INTRON, which is marketed by Schering-Plough Corporation. The increase in
royalties over the prior year was primarily due to the launch of PEG-INTRON
combination therapy in Japan in December 2004. Currently, PEG-INTRON combination
therapy is the only pegylated interferon-based combination therapy approved in
Japan.
Due to the December 2004 launch of PEG-INTRON in Japan, we believe
royalties from sales of PEG-INTRON may continue to increase over prior year
levels in the near term. In markets outside of Japan, PEG-INTRON combination
therapy competes directly with another pegylated interferon-based combination
therapy in a highly competitive market. Further, Schering-Plough has reported
that the overall hepatitis C market has been contracting. We cannot assure you
that these contracting and competitive market conditions will not offset the
positive impact of PEG-INTRON in Japan or that any particular sales levels of
PEG-INTRON will be achieved or maintained.
We expect North American sales of ABELCET may continue to be negatively
impacted by the increasingly competitive conditions in the intravenous
antifungal market, namely from the introduction of newer agents from Pfizer,
Merck, and Fujisawa, as well as increased pricing pressure in the market for
lipid formulations of amphotericin B. We cannot assure you that any particular
sales levels of ABELCET, ADAGEN, DEPOCYT, and ONCASPAR will be achieved or
maintained.
Contract revenues for the three months ended March 31, 2005 were
$452,000 as compared to $248,000 for the three months ended March 31, 2004. The
increase was principally due to revenue related to an agreement with Pharmagene
plc to apply our PEGylation technology to engineer a long-acting version of
Pharmagene's drug candidate, PGN0052.
During the three months ended March 31, 2005, we had export sales and
royalties on export sales of $12.4 million, of which $8.9 million were in
Europe. Export sales and royalties recognized on export sales for the three
months ended March 31, 2004 were $9.2 million, of which $7.5 million were in
Europe.
COST OF PRODUCT SALES AND MANUFACTURING REVENUE. Cost of product sales
and manufacturing revenue, as a percentage of net product sales and
manufacturing revenue, improved to 35% for the three months ended March 31, 2005
as compared to 38% for the same period last year. The decrease was due to
reduced ABELCET costs, as well as improved margins for ADAGEN, ONCASPAR, and
DEPOCYT. For each of the three month periods ended March 31, 2005 and March 31,
2004, we have included $1.1 million in cost of product sales and manufacturing
revenue, which related to the amortization of intangible assets acquired in
connection with the ABELCET acquisition during November 2002.
RESEARCH AND DEVELOPMENT. Research and development expenses consist
primarily of salaries and benefits; patent filing fees; contractor and
consulting fees, principally related to clinical and regulatory projects; costs
related to research and development partnerships or licenses; drug supplies for
clinical and preclinical activities; as well as other research supplies and
allocated facilities charges.
For the three months ended March 31, 2005, research and development
expenses increased by $2.2 million to $12.9 million as compared to $10.8 million
for the three months ended March 31, 2004. The increase in research and
development expenses was primarily due to increased costs related to MARQIBO of
$3.3 million, which included the impact of a $5.0 million payment made to Inex
Pharmaceuticals Corporation in March 2005 related to the termination of our
partnership for the development and commercialization of MARQIBO. The increased
research and development costs related to MARQIBO were partially offset by
reduced expenditures of approximately $1.1 million, which were primarily due to
the discontinuation of certain research and development programs, including our
clinical development program for Pegamotecan, which was discontinued in February
2005.
16
SELLING, GENERAL AND ADMINISTRATIVE. Selling expenses consist primarily
of salaries and benefits for our sales and marketing personnel, as well as other
commercial expenses and marketing programs to support our sales force. General
and administrative expenses consist primarily of salaries and benefits; outside
professional services for accounting, audit, tax, legal, and investor
activities; and allocations of facilities costs.
For the three months ended March 31, 2005 selling, general and
administrative expenses increased by $1.2 million to $13.7 million, as compared
to $12.5 million for the three months ended March 31, 2004. The increase was
primarily attributable to increased sales and marketing costs of approximately
$792,000 and increased general and administrative costs of approximately
$366,000. The increase in sales and marketing costs was comprised of a $1.2
million increase in costs related to our oncology sales operations, a $441,000
increase in costs related to MARQIBO, and an $808,000 decrease in costs related
to our hospital-based sales operations. The increase in general and
administrative costs was primarily attributable to an increase of $242,000 in
legal and accounting fees and a net increase of $124,000 in other costs.
Based on the increasingly competitive conditions in the intravenous
antifungal market, as previously discussed, as well as the discontinuation of
certain research and development projects, in April 2005 we reported that we are
realigning our cost structure through a restructuring. As a result of the
restructuring, we expect to incur charges of $1.5 million to $2.5 million during
the quarter ending June 30, 2005. These costs all involve cash expenditures and
are comprised primarily of employee termination benefits.
AMORTIZATION. Amortization expense is related to intangible assets
acquired in connection with the ABELCET acquisition in November 2002.
Amortization expense remained unchanged at $3.4 million for each of the three
month periods ended March 31, 2005 and 2004. A portion of amortization expense
is classified in cost of product sales and manufacturing revenue, as discussed
above. Amortization of intangible assets is calculated on a straight-line basis
over the estimated lives of the assets, which range from 3 to 15 years.
ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT. Acquired in-process
research and development for the three months ended March 31, 2004 of $12.0
million was due to an up-front payment to Inex related to the execution of a
strategic partnership and related agreements entered into with Inex related to
MARQIBO (a development-stage product). As previously discussed, this partnership
was terminated in March 2005.
OTHER INCOME (EXPENSE). Other income (expense) for the three months
ended March 31, 2005 was an expense of $7.1 million, as compared to income of
$6.3 million for the three months ended March 31, 2004. Other income (expense)
includes: net investment income, interest expense, and other expense.
Net investment income decreased by $10.5 million to $1.1 million for
the three months ended March 31, 2005 compared with $11.6 million for the three
months ended March 31, 2004. The decrease was principally due to the prior
year's sale of 880,075 shares of Nektar Therapeutics common stock, which
resulted in a net gain of approximately $11.0 million in the three months ended
March 31, 2004.
Interest expense was $5.0 million for each of the three months ended
March 31, 2005 and 2004. Interest expense is related to $400.0 million in 4.5%
convertible subordinated notes, which were outstanding for each of the three
month periods ended March 31, 2005 and 2004.
Other expense increased to $3.2 million for the three months ended
March 31, 2005, as compared to $337,000 for the three months ended March 31,
2004. The increase in the expense was related to a realized loss on the
liquidation of 375,000 shares of our investment in NPS common stock during the
quarter ended March 31, 2005, as well as an increase in the unrealized loss
associated with a derivative instrument we formed as a protective collar
arrangement to reduce our investment risk associated with our investment in
these shares.
INCOME TAXES. During the three months ended March 31, 2005, we
recognized a tax benefit of approximately $2.7 million, as compared to a tax
benefit of $5.5 million for the three months ended March 31, 2004. We recognized
a tax benefit for the three months ended March 31, 2005 at an estimated annual
effective tax rate of 37%, which is based on the projected income tax benefit
and taxable loss for the fiscal year ending June 30, 2005.
During the three months ended March 31, 2004, the Company recorded a
net tax benefit of approximately $5.5 million related primarily to the reversal
of a $3.8 million deferred tax asset valuation allowance for the write-down in a
prior year of Enzon's equity investment in Nektar Therapeutics, which was sold
during the quarter ended March 31, 2004. The sale resulted in a gain of
approximately $11.0 million. The benefit was also due to the reduction of
Enzon's estimated taxable income and effective tax rate to 29% as compared to
35% used in previous quarters and a payment during the three months ended March
31, 2004 of $12.0 million to Inex Pharmaceuticals related to acquired in-process
research and development.
17
NINE MONTHS ENDED MARCH 31, 2005 AND 2004
REVENUES. Total revenues for the nine months ended March 31, 2005 were
$122.1 million, as compared to $126.7 million for the nine months ended March
31, 2004. The components of revenues are product sales, manufacturing revenue,
royalties we earn on the sale of our products by others and contract revenues.
Net product sales decreased by 6% to $75.7 million for the nine months
ended March 31, 2005, as compared to $80.7 million for the nine months ended
March 31, 2004. The decrease in sales was due to decreased sales of ABELCET(R).
Sales of ABELCET in North America decreased by $10.7 million to $39.9 million
for the nine months ended March 31, 2005, as compared to $50.6 million for the
nine months ended March 31, 2004 due to weaker demand for the product as a
result of increased competition in the intravenous antifungal market. Sales of
DEPOCYT increased by $1.8 million to $5.8 million for the nine months ended
March 31, 2005 as compared to $4.0 million for the nine months ended March 31,
2004. DEPOCYT'S growth over the prior year was primarily attributable to
increased sales and marketing efforts and to a lesser extent a higher weighted
average price. Sales of ONCASPAR increased by $2.0 million to $15.3 million for
the nine months ended March 31, 2005, as compared to $13.3 million for the nine
months ended March 31, 2004. The increase in sales of ONCASPAR over the prior
year was due to a higher weighted average price as well as increased sales and
marketing efforts. Sales of ADAGEN increased by $1.9 million to $14.7 million
for the nine months ended March 31, 2005 as compared to $12.8 million for the
nine months ended March 31, 2004 due to an increase in the number of patients
receiving ADAGEN therapy and the timing of shipments.
Manufacturing revenue for the nine months ended March 31, 2005
increased by $3.5 million to $12.3 million, as compared to $8.8 million for the
comparable period of the prior year due to the timing of orders from our
contract manufacturing customers. Manufacturing revenue is related to the
manufacture and sale of ABELCET for the international market and other
manufacturing revenue.
Royalties for the nine months ended March 31, 2005, decreased to $32.9
million as compared to $36.4 million for the nine months ended March 31, 2004.
The decrease was primarily due to decreased sales of PEG-INTRON by
Schering-Plough, our marketing partner, due to competitive pressure from another
pegylated alpha interferon product and contracting market conditions. The
competitive and contracting market conditions were partially offset by the
launch of PEG-INTRON combination therapy in Japan in December 2004.
Contract revenues for the nine months ended March 31, 2005 increased by
$394,000 to $1.2 million as compared to $769,000 for the nine months ended March
31, 2004 principally due to revenue related to an agreement we entered into with
Pharmagene to apply our PEGylation technology to engineer a long-acting version
of Pharmagene's drug candidate, PGN0052.
During the nine months ended March 31, 2005, we had export sales and
royalties on export sales of $34.9 million, of which $26.0 million were in
Europe. Export sales and royalties recognized on export sales for the prior year
were $28.0 million, of which $23.4 million were in Europe.
COST OF PRODUCT SALES AND MANUFACTURING REVENUE. Cost of product sales
and manufacturing revenue, as a percentage of net sales and manufacturing
revenue, decreased to 37% for the nine months ended March 31, 2005 compared to
39% for the nine months ended March 31, 2004 due to lower ABELCET costs. For
each of the nine month periods ended March 31, 2005 and March 31, 2004, we have
included $3.4 million in cost of product sales and manufacturing revenue, which
related to the amortization of intangible assets acquired in connection with the
ABELCET acquisition during November 2002.
RESEARCH AND DEVELOPMENT. Research and development expenses increased
by $7.2 million to $31.9 million for the nine months ended March 31, 2005, as
compared to $24.7 million for the nine months ended March 31, 2004. The increase
in research and development expenses was primarily due to $6.2 million in costs
related to MARQIBO, which included the impact of a $5.0 million payment made to
Inex in March 2005 related to the termination of our partnership, and an
increase of $2.0 million in employee compensation expenses. These increases were
partially offset by a $1.0 million decrease in costs due to the discontinuation
of research and development programs, including our clinical development program
for Pegamotecan, which was discontinued in February 2005.
18
SELLING, GENERAL AND ADMINISTRATIVE. Selling, general and
administrative expenses increased by $4.4 million to $39.6 million for the nine
months ended March 31, 2005, as compared to $35.2 million for the nine months
ended March 31, 2004. The increase was primarily attributable to a $4.5 million
increase in sales and marketing costs, which was comprised of a $3.4 million
increase in costs related to our oncology sales operations, a $1.3 million
increase in costs related to MARQIBO, and a $300,000 decrease in costs related
to our hospital-based sales operations.
AMORTIZATION. Amortization expense remained unchanged at $10.1 million
for the nine months ended March 31, 2005 and 2004. Amortization expense for both
periods relates to intangible assets acquired in connection with the ABELCET
acquisition during November 2002. A portion of amortization is classified in
cost of product sales and manufacturing revenue. Amortization of intangible
assets is calculated on a straight-line basis over the estimated lives of the
assets, which range from 3 to 15 years.
ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT. Acquired in-process
research and development was $12.0 million for the nine months ended March 31,
2004 due to an up-front payment, which we made in January 2004 for the execution
of an agreement with Inex for the development and commercialization of MARQIBO.
As previously discussed, this partnership was terminated in March 2005.
OTHER INCOME (EXPENSE). Other income (expense) for the nine months
ended March 31, 2005 was an expense of $17.2 million, as compared to an expense
of $2.1 million for the nine months ended March 31, 2004. Other income (expense)
includes: net investment income, interest expense, and other income (expense).
Net investment income for the nine months ended March 31, 2005
decreased to $2.9 million from $12.7 million for the nine months ended March 31,
2004. The decrease was principally due to the prior year's sale of 880,075
shares of Nektar Therapeutics common stock, which resulted in a net gain of
approximately $11.0 million recorded in the nine months ended March 31, 2004.
This decrease was offset in part by $1.2 million increase in interest income for
the nine months ended March 31, 2005, as compared to the nine months ended March
31, 2004.
Interest expense was $14.9 million for each of the nine months ended
March 31, 2005 and 2004. Interest expense is related to $400.0 million in 4.5%
convertible subordinated notes, which were outstanding for both periods.
Other expense amounted to $5.2 million for the nine months ended March
31, 2005, as compared to other income of $71,000 for the nine months ended March
31, 2004. The increase in the expense was related to a realized loss on the
liquidation of 750,000 shares of our investment in NPS common stock during the
nine months ended March 31, 2005, which was offset in part by an increase in the
unrealized loss associated with a derivative instrument we formed as a
protective collar arrangement to reduce our risk associated with our investment
in these shares.
INCOME TAXES. During the nine months ended March 31, 2005 we recognized
a tax benefit of $3.3 million compared to a tax benefit of $2.7 million, for the
nine months ended March 31, 2004. We recognized a tax benefit for the nine
months ended March 31, 2005 at an estimated annual effective tax rate of 37%,
which is based on the projected income tax benefit and taxable loss for the
fiscal year ending June 30, 2005.
During the nine months ended March 31, 2004, the Company recorded a net
tax benefit of approximately $2.7 million related primarily to the reversal of a
$3.8 million deferred tax asset valuation allowance for the write-down in a
prior year of Enzon's equity investment in Nektar Therapeutics, which was sold
during the nine months ended March 31, 2004. The sale resulted in a gain of
approximately $11.0 million. The benefit was also due to the reduction of
Enzon's estimated taxable income and effective tax rate to 29% as compared to
35% used in previous quarters and a payment during the three months ended March
31, 2004 of $12.0 million to INEX Pharmaceuticals related to acquired in-process
research and development.
CRITICAL ACCOUNTING POLICIES
In December 2001, the U.S. Securities and Exchange Commission ("SEC")
requested that all registrants discuss their most "critical accounting policies"
in Management's Discussion and Analysis of Financial Condition and Results of
Operations. The SEC indicated that a "critical accounting policy" is one which
is both important to the portrayal of a company's financial condition and
results of operations and requires management's most difficult, subjective or
complex judgments, often as a result of the need to make estimates about the
effect of matters that are inherently uncertain.
19
Our consolidated financial statements are presented in accordance with
accounting principles that are generally accepted in the United States. All
professional accounting standards effective as of March 31, 2005 have been taken
into consideration in preparing the consolidated financial statements. The
preparation of the consolidated financial statements requires estimates and
assumptions that affect the reported amounts of assets, liabilities, revenues,
expenses and related disclosures including those related to contingent assets
and liabilities. Some of those estimates are subjective and complex, and,
consequently, actual results could differ from those estimates. The following
accounting policies have been highlighted as significant because changes to
certain judgments and assumptions inherent in these policies could affect our
consolidated financial statements.
Revenue from product sales and manufacturing revenue is recognized upon
passage of title and risk of loss to customers. This is generally at the time
products are shipped to customers. Provisions for discounts or chargebacks,
rebates and sales incentives to customers, and returns and other adjustments are
provided for in the period the related sales are recorded. Historical data is
readily available and reliable, and is used for estimating the amount of the
reduction in gross sales.
The majority of our net product sales are to wholesale distributors who
resell the products to the end customers. We provide chargeback payments to
these distributors based on their sales to members of buying groups at prices
determined under a contract between Enzon and the member. Administrative fees
are paid to buying groups based on the total amount of purchases by their
members. Chargeback amounts are based upon the volume of purchases multiplied by
the difference between the wholesaler acquisition cost and the contract price
for a product. We estimate the amount of the chargeback that will be paid using
historical trends, adjusted for current changes, and record the amounts as a
reduction to accounts receivable and a reduction of gross sales when we record
the sale of the product. The settlement of the chargebacks generally occurs
within three months after the sale to the wholesaler. We regularly analyze the
historical chargeback trends and make adjustments to recorded reserves for
changes in trends.
In addition, state agencies, which administer various programs, such as
the U.S. Medicaid and Medicare program, also receive rebates. Medicaid rebates
and administrative fees are recorded as a liability and a reduction of gross
sales when we record the sale of the product. Medicaid rebates are typically
paid within six to nine months after sale. In determining the appropriate
accrual amount we consider our historical Medicaid rebate and administration fee
payments by product as a percentage of our historical sales as well as any
significant changes in sales trend. Current Medicaid rebate laws and
interpretations, and the percentage of our products that are sold to Medicaid
patients are also evaluated. Factors that complicate the rebate calculations are
the timing of the average manufacturer pricing computation, the estimated lag
time between sale and payment of a rebate and the level of reimbursement by
state agencies.
The following is a summary of reductions of gross sales accrued as of
March 31, 2005 and June 30, 2004 (the end of our last fiscal year):
March 31, 2005 June 30, 2004
---------------------- ---------------------
Accounts Receivable Reductions
Chargebacks $6,812 $7,802
Cash Discounts 183 414
Other (including returns) 1,407 1,323
---------------------- ---------------------
Total $8,402 $9,539
---------------------- ---------------------
Accrued Liabilities
Medicaid Rebates $2,299 $2,011
Administrative Fees 425 640
---------------------- ---------------------
Total $2,724 $2,651
---------------------- ---------------------
There were no revisions to the estimates for gross to net sales
adjustments that would be material to income from operations for the three and
nine months ended March 31, 2005 and 2004.
Royalties under our license agreements with third parties are
recognized when earned through the sale of the product by the licensee net of
any estimated future credits, chargebacks, sales discount rebates and refunds.
20
Contract revenues are recorded as the earnings process is completed.
Non-refundable milestone payments that represent the completion of a separate
earnings process are recognized as revenue when earned, upon the occurrence of
contract-specified events and when the milestone has substance. Non-refundable
payments received upon entering into licenses and other collaborative agreements
where we have continuing involvement are recorded as deferred revenue and
recognized ratably over the estimated service period.
Under the asset and liability method of Statement of Financial
Accounting Standards ("SFAS") No. 109 "Accounting for Income Taxes", deferred
tax assets and liabilities are recognized for the estimated future tax
consequences attributable to differences between financial statement carrying
amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. A valuation allowance on
net deferred tax assets is provided for when it is more likely than not that
some portion or all of the deferred tax assets will not be realized. We have
significant net deferred tax assets, primarily related to net operating loss and
other carryforwards. Events, such as a sustained decline in the Company's
product revenues and/or increased expenses could result in a revision to the
Company's projected future taxable income, and accordingly, the need for a
valuation allowance based upon the ultimate realizability of its net operating
loss carryforwards, research and development tax credits and other deferred tax
assets. The Company's federal and state operating loss carryforwards will begin
to expire in 2009 and 2006, respectively, and the federal and state research and
development credits will begin to expire in 2006 and 2021, respectively. The
Company will continue to assess the need for such valuation allowance based on
analyses of operating results and projections of future operating performance of
the Company.
We assess the carrying value of our cost method investments in
accordance with SFAS No. 115 "Accounting for Certain Investments in Debt and
Equity" and SEC Staff Accounting Bulletin ("SAB") No. 59 "Accounting for
Non-current Marketable Equity Securities". An impairment write-down is recorded
when a decline in the value of an investment is determined to be
other-than-temporary. These determinations involve a significant degree of
judgment and are subject to change as facts and circumstances change.
In accordance with the provisions of SFAS No. 142 "Goodwill and other
Intangible Assets", goodwill and intangible assets determined to have an
indefinite useful life acquired in a purchase business combination are not
subject to amortization, are tested at least annually for impairment, and are
tested for impairment more frequently if events and circumstances indicate that
the asset might be impaired. We completed our annual goodwill impairment test on
May 31, 2004, which indicated that goodwill was not impaired. An impairment loss
is recognized to the extent that the carrying amount exceeds the asset's fair
value. Because the Company is in one reporting unit, this determination is made
at the Company level and consists of two steps. First, we determine the fair
value of our reporting unit and compare it to its carrying amount. Second, if
the carrying amount of its reporting unit exceeds our fair value, an impairment
loss is recognized for any excess of the carrying amount of the reporting unit's
goodwill over the implied fair value of that goodwill. The implied fair value of
goodwill is determined by allocating the fair value of the reporting unit in a
manner similar to a purchase price allocation, in accordance with SFAS No. 141,
"Business Combinations". The residual fair value after this allocation is the
implied fair value of our goodwill. Recoverability of amortizable intangible
assets is determined by comparing the carrying amount of the asset to the future
undiscounted net cash flow to be generated by the asset. The evaluations involve
amounts that are based on management's best estimate and judgment. Actual
results may differ from these estimates. If recorded values are less than the
fair values, no impairment is indicated. SFAS No. 142 also requires that
intangible assets with estimated useful lives be amortized over their respective
estimated useful lives.
We apply the intrinsic value-based method of accounting prescribed by
Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued
to Employees", and related interpretations, in accounting for our fixed plan
stock options. As such, compensation expense would be recorded on the date of
grant of options to employees and members of the Board of Directors only if the
current market price of the underlying stock exceeded the exercise price. SFAS
No. 123, "Accounting for Stock-Based Compensation", established accounting for
stock-based employee compensation plans. As allowed by SFAS No. 123, we have
elected to continue to apply the intrinsic value-based method of accounting
described above, and have adopted the disclosure requirements of SFAS No. 123,
as amended in December 2004.
When the exercise price of employee or director stock options is less
than the fair value of the underlying stock on the grant date, we record
deferred compensation for the difference and amortize this amount to expense
over the vesting period of the options. Options or stock awards issued to
non-employees and consultants are recorded at their fair value as determined in
accordance with SFAS No. 123 and EITF No. 96-18, "Accounting for Equity
Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services", and recognized over the related
vesting period.
21
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS (CAUTIONARY STATEMENTS UNDER
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995)
Management's Discussion and Analysis of Financial Condition and Results
of Operations contains "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. Forward-looking statements relate to
expectations or forecasts of future events. These statements use words such as
"anticipate," "believe," "could," "estimate," "expect," "forecast," "project,"
"intend," "plan," "potential," "will," and other words and terms of similar
meaning in connection with a discussion of potential future events or
circumstances or future operating or financial performance. You can also
identify forward-looking statements by the fact that they do not relate strictly
to historical or current facts.
Specific examples of such forward looking statements include statements
in this report relating to the potential impact on our revenues of
Schering-Plough's launch of PEG-INTRON in Japan, the potential impact on our
ability to sustain or grow our ABELCET revenues in light of continuing
competitive and pricing pressure in the intravenous antifungal market, the
future sales performance of our other products, the potential impact of the
manufacturing and stability problems with ONCASPAR we continue to experience,
the performance of our protective collar arrangement relating to the shares of
NPS common stock we hold, the continued sufficiency of our capital resources and
our ability to access the capital markets in the future. This is not necessarily
inclusive of all examples of forward looking statements that are or may be
contained in this report.
Any or all forward-looking statements contained in this discussion may
turn out to be wrong. Actual results may vary materially, and there are no
guarantees about our financial and operating performance or the performance of
our stock. All statements are made as of the date of signing of this report and
we do not assume any obligation to update any forward-looking statement.
Many factors could cause actual results to differ from the results or
developments discussed or predicted in the forward looking statements made in
this report. These factors include inaccurate assumptions and a broad variety of
other risks and uncertainties, including some that are known and some that are
not. Although it is not possible to predict or identify all such factors, many
of them are described under the caption "Risk Factors" in the "Management's
Discussion and Analysis of Financial Condition and Results of Operations"
section of our Annual Report on Form 10-K/A for the fiscal year ended June 30,
2004, which we filed with the SEC and which is incorporated herein by reference.
Readers of this report are advised to read such Risk Factors in connection with
this report. The following information supplements and updates such Risk
Factors:
o Although Schering-Plough has received approval for PEG-INTRON
in Japan in combination with REBETOL for the treatment of
hepatitis C, there can be no assurance that Schering-Plough
will successfully market PEG-INTRON in Japan. It is
anticipated that a competing pegylated interferon-based
combination therapy will receive marketing approval in Japan
for hepatitis C in the next one to two years. Even if
Schering-Plough is successful in launching PEG-INTRON in
Japan, it is likely that the future launch of a competing
pegylated interferon-based combination therapy will have a
negative impact on PEG-INTRON's Japanese market share and
sales.
o We have been experiencing increasing pricing pressure with
respect to ABELCET. In particular, Fujisawa Healthcare Inc.
and Gilead Sciences, Inc., which jointly market a competing
liposomal amphotericin B product have aggressively lowered the
price of their product in certain regions and for certain
customers in the U.S. This has resulted in the shrinkage or
loss of certain of our customer accounts. Further, ABELCET
sales may also continue to be negatively impacted by newer
agents from Pfizer, Merck, and Fujisawa. We are developing
strategies to address these competitive threats, but there
can be no assurance as to when or whether we will be
successful in stopping or reversing this trend.
o We have received a notice from Bristol-Myers Squibb Company
("BMS") terminating our amphotericin B supply agreement with
BMS effective March 1, 2006. We currently have an alternative
source of supply of amphotericin B and are seeking to qualify
at least one additional source of supply. The termination by
BMS may give rise to future increased costs for the
acquisition of amphotericin B as well as increased capital
expenditures related to readying a new supplier's facilities
for cGMP production and regulatory approval of ABELCET
incorporating the alternative amphotericin B. Although there
can be no assurance as to the timing of these increased costs
and additional capital expenditures, we anticipate that these
may be incurred beginning in calendar 2007.
22
o Manufacturing and stability problems required us to implement
a voluntary recall for one ONCASPAR batch March 2005. To date,
we have been unable to identify the cause of the manufacturing
and stability problems related to the batches of ONCASPAR that
we voluntarily recalled in March 2005, September 2004, and
July 2004 and preliminary indicators do not rule out that an
additional batch of ONCASPAR may also be affected by
manufacturing and stability problems, which we may also
voluntarily recall in the near term. We cannot assure you that
future product recalls will not materially adversely affect
our business, our financial conditions, results of operations
or our reputation and relationships with our customers.
23
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The following discussion about our exposure to market risk of financial
instruments contains forward-looking statements. Actual results may differ
materially from those described.
Our holdings of financial instruments are comprised of debt securities
and time deposits. All such instruments are classified as securities
available-for-sale. In August 2003, we entered into a Zero Cost Protective
Collar arrangement with a financial institution to reduce the exposure
associated with the 1.5 million shares of common stock of NPS we received as
part of the merger termination agreement with NPS. The terms of the collar
arrangement are structured so that our investment in NPS stock, when combined
with the value of the collar, should secure ultimate cash proceeds in the range
of 85% - 108% of the negotiated fair value per share of $23.47 (representing a
4.85% discount off the closing price of NPS common stock on the day before the
collar was executed) (See Note 12 to our unaudited condensed consolidated
financial statements). We do not invest in portfolio equity securities or
commodities or use financial derivatives for trading purposes. Our debt security
portfolio represents funds held temporarily pending use in our business and
operations. We manage these funds accordingly. We seek reasonable assuredness of
the safety of principal and market liquidity by investing in rated fixed income
securities while at the same time seeking to achieve a favorable rate of return.
Our market risk exposure consists principally of exposure to changes in interest
rates. Our holdings are also exposed to the risks of changes in the credit
quality of issuers. We typically invest the majority of our investments in the
shorter-end of the maturity spectrum, and at March 31, 2005 all of our holdings
were in instruments maturing in four years or less.
The table below presents the principal amounts and related weighted
average interest rates by year of maturity for our investment portfolio as of
March 31, 2005 (in thousands):
2006 2007 2008 2009 TOTAL FAIR VALUE
-------- ------- -------- -------- --------- -----------
Fixed Rate $103,454 $37,259 $18,586 $11,025 $170,324 $168,879
Average Interest Rate 0.92% 2.14% 2.54% 2.82% 1.49% -
Variable Rate - - - - - -
Average Interest Rate - - - - - -
--------- ------- -------- -------- --------- -----------
$103,454 $37,259 $18,586 $11,025 $170,324 $168,879
========= ======= ======== ======== ========= ===========
Our 4.5% convertible subordinated notes in the principal amount of
$400.0 million due July 1, 2008 have fixed interest rates. The fair value of the
notes was approximately $360.0 million at March 31, 2005. The fair value of
fixed interest rate convertible notes is affected by changes in interest rates
and by changes in the price of our common stock.
24
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES.
Under the supervision and with the participation of our management,
including our Chief Executive Officer and our Controller (Acting Principal
Accounting Officer), we evaluated the effectiveness of the design and operation
of our disclosure controls and procedures (as defined in Rule 13a-15(e) under
the Exchange Act) as of March 31, 2005, the end of the period covered by this
report (the "Evaluation Date"). Based upon that evaluation, the Chief Executive
Officer and Controller concluded that, as of the Evaluation Date, our disclosure
controls and procedures were effective in timely alerting them to the material
information required to be included in our periodic SEC filings.
CHANGES IN INTERNAL CONTROLS
There were no changes in our internal controls over financial reporting
during the period covered by this report that have materially affected, or are
reasonably likely to materially affect our internal control over financial
reporting.
25
PART II OTHER INFORMATION
ITEM 6. EXHIBITS
(a) Exhibits required by Item 601 of Regulation S-K.
EXHIBIT
NUMBER DESCRIPTION
3.1 Certificate of Incorporation, as amended (previously filed as an
exhibit to the Company's Annual Report on Form 10-K for the year ended
June 30, 2002 and incorporated herein by reference thereto)
3.2 Amendment to Certificate of Incorporation (previously filed as an
exhibit to the Company's Current Report on Form 8-K filed on December
10, 2002 and incorporated herein by reference thereto)
3.3 By laws, as amended (previously filed as an exhibit to the Company's
Current Report on Form 8-K filed with the Commission on May 22, 2002
and incorporated herein by reference thereto)
4.1 Indenture dated as of June 26, 2001, between the Company and
Wilmington Trust Company, as trustee, including the form of 4 1/2%
Convertible Subordinated Notes due 2008 attached as exhibit A thereto
(previously filed as an exhibit to the Company's Registration
Statement on Form S-3 (File No. 333-67509) filed with the Commission
and incorporated herein by reference thereto)
4.2 Rights Agreement dated May 17, 2002 between the Company and
Continental Stock Transfer Trust Company, as rights agent (previously
filed as an exhibit to the Company's Form 8-A (File No. 000-12957)
filed with the Commission on May 22, 2002 and incorporated herein by
reference thereto)
4.3 First Amendment to Rights Agreement, dated as of February 19, 2003
(previously filed as an exhibit to the Company's Form 8-A12 G/A (File
No. 000-12957) filed with the Commission on February 20, 2003 and
incorporated herein by reference thereto)
10.2 Employment Agreement with Craig A. Tooman dated January 5, 2005
(previously filed as an exhibit to the Company's Quarterly Report on
Form 10-Q for the quarter ended December 31, 2004 and incorporated
herein by reference thereto)
10.6 Form of Restricted Stock Unit Award Agreement for Executive Officers *
31.1 Certification of Principal Executive Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 *
31.2 Certification of Principal Accounting Officer pursuant to Section 302
of the Sarbanes-Oxley Act.*
32.1 Certification of Principal Executive Officer pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 *
32.2 Certification of Principal Accounting Officer pursuant to Section 906
of the Sarbanes-Oxley Act.*
* Filed herewith.
26
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ENZON PHARMACEUTICALS, INC.
(Registrant)
By: /S/JEFFREY H. BUCHALTER
---------------------------------------
President and Chief Executive Officer
(Principal Executive Officer)
Date: May 10, 2005 By: /S/TONI L. KLICH
---------------------------------------
Controller
(Acting Principal Accounting Officer)
27
ENZON
685 Route 202/206, Bridgewater, NJ 08807
(908) 541-8600 o FAX: (908) 575-9457
HTTP://WWW.ENZON.COM